CXCL9 and neoplasm: Preclinical studies have illustrated that chemokines C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 predominantly drive the recruitment of activated CD8+ T cells into tumor sites by engaging the corresponding chemokine receptor CXCR3 expressed on immune cells, with CXCL10 being more abundantly expressed (38, 40, 41).